Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-κB and elevates ICAM-1 expression in Caco-2 cells

Lipids

Volumn 42, Issue 8, 2007, Pages 687-698

  Ramakers, Julian D ^a   Mensink, Ronald P ^a   Schaart, Gert ^a   Plat, Jogchum ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Caco 2 cells; Intestinal inflammation; Peroxisome proliferator activated receptor (PPAR); Prostaglandins

Indexed keywords

ARACHIDONIC ACID (ARA); CACO-2 CELLS; INTESTINAL INFLAMMATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR); PROSTAGLANDINS;

CELL ADHESION; DISEASES; FATTY ACIDS; OILS AND FATS; TRANSCRIPTION FACTORS;

ENZYME ACTIVITY;

ANGIOGENIN; ARACHIDONIC ACID; DEXAMETHASONE; FATTY ACID; GW 7647; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOLIPID DERIVATIVE; SALAZOSULFAPYRIDINE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CACO-2 CELLS; EICOSAPENTAENOIC ACID; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; NF-KAPPA B; OLEIC ACID; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHOLIPIDS; TRANSFECTION;

EID: 34548213672     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-007-3071-3     Document Type: Article

References (54)

1. Kromann N, Green A (1980) Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 208:401-406
2. Shoda R, Matsueda K, Yamato S, Umeda N (1996) Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 63:741-745
3. Belluzzi A (2002) n-3 Fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc 61:391-395
4. Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M (1987) Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut 28:1002-1007
5. Buhner S, Nagel E, Korber J, Vogelsang H, Linn T, Pichlmayr R (1994) Ileal and colonic fatty acid profiles in patients with active Crohn's disease. Gut 35:1424-1428
6. Pacheco S, Hillier K, Smith C (1987) Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease. Clin Sci (Lond) 73:361-364
7. Fernandez-Banares F, Esteve-Comas M, Mane J, Navarro E, Bertran X, Cabre E, Bartoli R, Boix J, Pastor C, Gassull MA (1997) Changes in mucosal fatty acid profile in inflammatory bowel disease and in experimental colitis: a common response to bowel inflammation. Clin Nutr 16:177-183
8. Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83:1505S-1519S
9. Hulshof KFAM, Jansen-van der Vliet M, Westenbrink S, Doest tD (2004) De inneming van vetzuren en vetzuurclusters (voedselconsumptiepeiling 1997-1998). TNO Voeding, Zeist
10. Li B, Birdwell C, Whelan J (1994) Antithetic relationship of dietary arachidonic acid and eicosapentaenoic acid on eicosanoid production in vivo. J Lipid Res 35:1869-1877
11. Zhou L, Nilsson A (2001) Sources of eicosanoid precursor fatty acid pools in tissues. J Lipid Res 42:1521-1542
12. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, Malkinson C, Shaheen MZ, Willars JE (1992) Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33:922-928
13. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M (1996) Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334:1557-1560
14. MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, Hilton LG, Gralnek IM, Rhodes S, Khanna P et al. (2005) Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 82:611-619
15. Bernstein CN, Sargent M, Gallatin WM (1998) Beta2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 86:147-160
16. Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP (1997) Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol 32:480-486
17. Matsuzawa J, Sugimura K, Matsuda Y, Takazoe M, Ishizuka K, Mochizuki T, Seki SS, Yoneyama O, Bannnai H, Suzuki K, et al. (2003) Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut 52:75-78
18. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K (1999) Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 117:462-468
19. Rijcken E, Krieglstein CF, Anthoni C, Laukoetter MG, Mennigen R, Spiegel HU, Senninger N, Bennett CF, Schuermann G (2002) ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 51:529-535
20. van Deventer SJ, Tami JA, Wedel MK (2004) A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53:1646-1651
21. Schreiber S (2005) The complicated path to true causes of disease: role of nuclear factor kappaB in inflammatory bowel disease. Gut 54:444-445
22. Neurath MF, Becker C, Barbulescu K (1998) Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 43:856-860
23. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290
24. Gan HT, Chen YQ, Ouyang Q (2005) Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J Gastroenterol Hepatol 20:1016-1024
25. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K (2000) Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95:3452-3457
26. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115:357-369
27. Schreiber S, Nikolaus S, Hampe J (1998) Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 42:477-484
28. De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, Adda S, Hoffman J, Kahoud N, Garlapati R, et al. (2007) Nonviral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 56:524-533
29. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2:998-1004
30. Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749
31. Thijssen MA, Malpuech-Brugere C, Gregoire S, Chardigny JM, Sebedio JL, Mensink RP (2005) Effects of specific CLA isomers on plasma fatty acid profile and expression of desaturases in humans. Lipids 40:137-145
32. Wensing AG, Mensink RP, Hornstra G (1999) Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects. Br J Nutr 82:183-191
33. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917
34. Kaluzny MA, Duncan LA, Merritt MV, Epps DE (1985) Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res 26:135-140
35. Morrison WR, Smith LM (1964) Preparation Of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res 5:600-608
36. Parkos CA, Colgan SP, Diamond MS, Nusrat A, Liang TW, Springer TA, Madara JL (1996) Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: consequences for CD11b/CD 18-mediated interactions with neutrophils. Mol Med 2:489-505
37. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
38. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, Willson TM (2001) Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett 11:1225-1227
39. Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator- activated receptors in inflammation control. J Endocrinol 169:453-459
40. Teitelbaum J, Walker W (2001) Review: the role of omega 3 fatty acids in intestinal inflammation. J Nutr Biochem 12:21-32
41. Camandola S, Leonarduzzi G, Musso T, Varesio L, Carini R, Scavazza A, Chiarpotto E, Baeuerle PA, Poli G (1996) Nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid. Biochem Biophys Res Commun 229:643-647
42. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 284:L84-89
43. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr. Libby P (1994) The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 14:1829-1836
44. Hughes DA, Southon S, Pinder AC (1996) (n-3) Polyunsaturated fatty acids modulate the expression of functionally associated molecules on human monocytes in vitro. J Nutr 126:603-610
45. Miles EA, Wallace FA, Calder PC (2000) Dietary fish oil reduces intercellular adhesion molecule 1 and scavenger receptor expression on murine macrophages. Atherosclerosis 152:43-50
46. Hughes DA, Pinder AC, Piper Z, Johnson IT, Lund EK (1996) Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr 63:267-272
47. Luyer MD, Buurman WA, Hadfoune M, Jacobs JA, Konstantinov SR, Dejong CH, Greve JW (2004) Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock. Shock 21:65-71
48. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
49. Poynter ME, Daynes RA (1998) Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841
50. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389
51. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403
52. Herfarth H, Goke M, Hellerbrand C, Muhlbauer M, Vogl D, Scholmerich J, Rogler G (2003) Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis 18:401-405
53. Stokkers PC, Hommes DW (2004) New cytokine therapeutics for inflammatory bowel disease. Cytokine 28:167-173
54. Braat H, Rottiers P, Huyghebaert N, Zelinkova Z, Remaut E, Remon JP, Deventer vS, Neirynck S, Peppelenbosch M, Steidler L et al. (2005) Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease. Gastroenterology 128:A104